CN105943700B - The Chinese medicine composition and its preparation method and application of numbness is led in a kind of kidney tonifying - Google Patents
The Chinese medicine composition and its preparation method and application of numbness is led in a kind of kidney tonifying Download PDFInfo
- Publication number
- CN105943700B CN105943700B CN201610432607.6A CN201610432607A CN105943700B CN 105943700 B CN105943700 B CN 105943700B CN 201610432607 A CN201610432607 A CN 201610432607A CN 105943700 B CN105943700 B CN 105943700B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- drug
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 65
- 210000003734 kidney Anatomy 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 231100000862 numbness Toxicity 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 201000008482 osteoarthritis Diseases 0.000 claims abstract description 14
- 239000009636 Huang Qi Substances 0.000 claims abstract description 11
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 8
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 8
- 241000237636 Pheretima Species 0.000 claims abstract description 8
- 241001148782 Davallia Species 0.000 claims abstract description 7
- 241000405911 Rehmannia glutinosa Species 0.000 claims abstract description 7
- 239000000126 substance Substances 0.000 claims abstract description 5
- 238000011282 treatment Methods 0.000 claims description 35
- 229940079593 drug Drugs 0.000 claims description 23
- 239000000463 material Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 238000012360 testing method Methods 0.000 abstract description 7
- 210000004369 blood Anatomy 0.000 description 28
- 239000008280 blood Substances 0.000 description 27
- 208000002193 Pain Diseases 0.000 description 25
- 230000036407 pain Effects 0.000 description 25
- 239000000243 solution Substances 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 16
- 230000017531 blood circulation Effects 0.000 description 13
- 230000001737 promoting effect Effects 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 210000000988 bone and bone Anatomy 0.000 description 10
- 230000006872 improvement Effects 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 239000013558 reference substance Substances 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 9
- 102100032752 C-reactive protein Human genes 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 210000003205 muscle Anatomy 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- 206010067484 Adverse reaction Diseases 0.000 description 6
- 208000006820 Arthralgia Diseases 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 230000006838 adverse reaction Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- 239000012085 test solution Substances 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 206010003549 asthenia Diseases 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 210000003127 knee Anatomy 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000003932 urinary bladder Anatomy 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 241001327284 Sorghastrum nutans Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000030208 low-grade fever Diseases 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241000212322 Levisticum officinale Species 0.000 description 1
- 201000000023 Osteosclerosis Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 description 1
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000012850 discrimination method Methods 0.000 description 1
- 238000007905 drug manufacturing Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000001645 levisticum officinale Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
- A61K36/126—Drynaria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a kind of Chinese medicine composition of logical numbness of kidney tonifying, and the Chinese medicine composition is made of each bulk pharmaceutical chemicals of following mass fraction: 15 parts of Rehmannia glutinosa, 15 parts of the rhizome of davallia, 30 parts of Radix Astragali, 15 parts of Radix Angelicae Sinensis, 15 parts of radix achyranthis bidentatae, 15 parts of Cortex Eucommiae, 12 parts of Rhizoma Chuanxiong, 12 parts, 12 parts of Radix Angelicae Pubescentis, 9 parts of pheretima of radix saposhnikoviae, 15 parts of Caulis Spatholobi, 12 parts of safflower.The present invention also provides preparation methods and application.Through testing, traditional Chinese medicine composition for treating Osteoarthritis clinical efficacy of the invention is significant.
Description
Technical field
The present invention relates to the Chinese medicine compositions and its preparation method and application that numbness is led in a kind of kidney tonifying.
Background technique
Osteoarthritis (Ostcoarthriti OA) is a kind of common Chronic Progressive arthritis, and pathological characteristic is
Articular cartilage degeneration, destruction, osteosclerosis under bone, joint margins and subchondral bone reactive hyperplasia, spur are formed.OA is more common in always
Year people, epidemiological survey show that its disease incidence in 55~64 years old crowd is 40%, the disease incidence in over-65s crowd
Up to 60%.With the increase of the world aged, OA disease incidence is also in the trend that rises year by year, and pain occurs in OA patient, joint becomes
Shape, serious person lead to physical disabilities, decline life of elderly person quality, bring the human body and mentally dual pain；These harm
It has attracted extensive attention.Its exact pathogenic factor is still unclear at present, on western medical treatment mostly based on suiting the medicine to the illness, relieve pain,
It is a small number of even to need replacement joint, the decline of greatly pain and quality of life is caused to patient.And Osteoarthritis
Treatment time it is longer, non-steroid anti-inflammatory drug, act on antirheumatic drug slowly, use of hormone etc. can make patient occur being difficult to take precautions against
Adverse reaction and paradox problem.It can cause upset,gastro-intestinal, dizziness, headache, alopecia, oral cavity using non-steroid anti-inflammatory drug
Ulcer, hepatic disfunction, bone marrow suppression etc. make patient be difficult to complete entire therapeutic scheme；The use of hormone can be such that patient occurs
Hormone dependant phenomenon, and during Hormone Withdrawal subtracts, there is disease relapse and touching refractory.All these toxic side effects all pole
The clinical treatment of Osteoarthritis is limited greatly, seriously affects the life quality of patient.
It is to play its comprehensive function from too many levels, multiple target point that traditional Chinese medicine, which treats Osteoarthritis, can not only promote bone shape
At, moreover it is possible to inhibit bone loss, and toxicity is small, be suitable for taking for a long time, at present just increasingly by common concern, application
Prospect is very wide.
Summary of the invention
The present invention provides the Chinese medicine compositions that numbness is led in a kind of kidney tonifying, for this purpose, the present invention also provides preparation method and answering
With.
In order to solve the problems in the existing technology, technical solution provided by the invention are as follows:
The Chinese medicine composition of numbness is led in a kind of kidney tonifying, and the Chinese medicine composition is made of each bulk pharmaceutical chemicals of following mass fraction:
15 parts of Rehmannia glutinosa, 15 parts of the rhizome of davallia, 30 parts of Radix Astragali, 15 parts of Radix Angelicae Sinensis, 15 parts of radix achyranthis bidentatae, 15 parts of Cortex Eucommiae, 12 parts of Rhizoma Chuanxiong, 12 parts of radix saposhnikoviae,
12 parts of Radix Angelicae Pubescentis, 9 parts of pheretima, 15 parts of Caulis Spatholobi, 12 parts of safflower.
The present invention also provides the preparation methods of above-mentioned Chinese medicine composition, and steps are as follows:
(1) Radix Astragali of formula ratio, rhizome of chuanxiong are ground into fine powder；
(2) remaining 10 taste is extracted with water 2 times, collecting decoction, after filtering, filtrate is condensed into thick paste;
(3) fine powder being added in step (1) mixes, and pill is made.
Preferably, it is the water extraction that 10 times are added in bulk pharmaceutical chemicals mixture that water described in step (2), which mentions,.
Preferably, it is to extract 2h for the first time that 2 times are extracted described in step (2), second of extraction 1h.
Preferably, in step (2) by filtrate be condensed into relative density be 1.30 ~ 1.35(60 DEG C) thick paste.
The present invention also provides application of the above-mentioned Chinese medicine composition in the drug that rheumatism is led in preparation treatment kidney tonifying.
The present invention also provides application of the above-mentioned Chinese medicine composition in the drug of preparation treatment Osteoarthritis.
The present invention also provides a kind of drug, effective component is Chinese medicine composition described in claim 1.
Preferably, the dosage form of the drug is pill.
Preferably, further including medically acceptable auxiliary material in the drug.
Chinese medicine composition of the invention is prepared into drug with any means in the prior art.Because containing effective
Ingredient has good therapeutic effect to Osteoarthritis so can effectively treat kidney tonifying leads to rheumatism.In the preparation, may be used also
The auxiliary material medically received is added.
Professor Meng Qingcai always works on the traditional Chinese medicine prevention research work of orthopaedics difficult and complicated illness for many years, in clinical studies
First by carrying out clinical observation and efficacy evaluation to a large amount of osteoarthritis patients；Pass through zoopery in infrastest
Come the mechanism of action and possible action pathway of research and discussion recipe, thus for we validity, safety, can apply and
Replicability provides the theoretical foundation and guarantee of science.Secondly, stagnant, the evil stasis of poison is superintended and directed according to kidney deficiency, the evil morbidity of inside and outside conjunction
Etiology and pathogenesis establishes the Clinical symptoms of above two disease based on asthenia in origin and asthenia in superficiality, and liver-kidney deficiency occupies in its interpretation of the cause, onset and process of an illness lapses to
In hinge status.In particular, kidney deficiency and liver is this, it is mark that blockage of channel, poison be evil, which to be retarded by silt, the weakened body resistance and domination of pathogen, and evidence " is controlled in treatment
Disease must be asked first in this " propose strengthening vital QI to eliminate pathogenic factors, the principle of reatment for the treatment of both manifestation and root cause of disease.Righting is to tonify the liver and kidney；Eliminating evil is logical superintends and directs
Eliminating evil dredging collateral, by wind-dispelling, cold dispelling, dampness removing, heat-clearing, resolving sputum, make by stasis of blood etc. heresy go then train of thought it is logical.The two complements each other, healthy tendency
Sheng Ze phlegm, the wet, stasis of blood, turbid all heresies is filled to go out certainly；Perverse trend is dispelled, then essence, saliva, gas, blood are full.According to above-mentioned principle of reatment, benefit is drafted
Kidney nourshing blood and promoting blood circulation, the therapy of active numbness relieving and pain relieving, recipe form Rehmannia glutinosa, the rhizome of davallia, Radix Astragali, Radix Angelicae Sinensis, radix achyranthis bidentatae, Cortex Eucommiae, Rhizoma Chuanxiong,
Radix Angelicae Pubescentis, radix saposhnikoviae, pheretima, Caulis Spatholobi, safflower.
The benefits of Rehmannia glutinosa in side: entering liver kidney and have nourishing yin and nourishing blood, life essence-filling, marrow-benefitting, " pearl sac " carry its " main replenishing blood and vital energy, nourshing kidney
Water, benefit it is Kidney-Yin, shin bone is ached after being ill ", Compendium of Material Medica cloud its " filling out marrow, long muscle, promoting vital essence and blood genernation, tonifying five zang organs ", " book on Chinese herbal medicine from
Newly " record " kidney nourishing water, packing marrow, help is Kidney-Yin ".It is agent on big tonifying yin blood saliva essence, enriching yin and nourishing kidney main ingredient；Close the rhizome of davallia:
The effect of bitter temperature enters liver kidney channel, and tool, which is invigorated blood circulation, continues muscle, nourishing disney and strengthening bone, " book on Chinese herbal medicine is stated ": " controls pain in the loins migratory arthralgia apoplexy arthroncus of knee contraction gas
Card ".This product energy promoting blood circulation to remove blood stasis, swelling and pain relieving, reunion of fractured tendons and bones are the key medicine of traumatology.Two medicine kidney-nourishings, which fill, superintends and directs, warm but not dry, yin-yang
Giving young employees remedial-courses in general knowledge and vocational skills is altogether monarch drug in a prescription.
Radix achyranthis bidentatae activating microcirculation and removing stasis medicinal, nourishing liver and kidney, strengthening the bones and muscles, sharp joint are walked and can be mended, and property is kind to draw all medicine downlinks, enter lower burnt blood system；
Cortex Eucommiae nourishing liver and kidney, strengthens the bone at strong governor vessel, mends without dry, " collected statements on the herbal foundation ": " the non-Cortex Eucommiae of the pain of waist and knee is not removed ", go directly lower burnt gas
Point；Two medicines share reinforcement nourishing liver and kidney, the function of strong logical muscles and bones.Raw Radix Astragali, Radix Angelicae Sinensis are strongly invigorating QI and blood, " control wind first to manage with Rhizoma Chuanxiong is existing
Blood, blood wind is from going out " meaning, and have the function for reaching kidney tonifying with invigorating the spleen indirectly.Above all medicines, play nourishing liver and kidney, strengthening the bones and muscles altogether, and QI invigorating is supported
Blood, promoting blood circulation reach strengthening vital QI to eliminate pathogenic factors, assist monarch drug in a prescription and are altogether ministerial drug.
Radix saposhnikoviae, pungent, sweet, tepor.Enter bladder, liver, the spleen channel.It expels pathogenic wind from the body surface, wins wet spasmolysis, antidiarrheal hemostasis.For rheumatism numbness
Bitterly." collected statements on the herbal foundation ": " radix saposhnikoviae, the medicine of dispersing wind and cold arthritis with fixed pain caused by dampness.Therefore unsuccessful, the skeletal pain in main all wind whole body, four limbs contraction urgency , Lou lame
The card such as epilepsy convulsion "." book on Chinese herbal medicine just ": " radix saposhnikoviae, with this person flat relieve heat of its gas, though bladder stomach meridian medicine, so with it is all through medicine, respectively through all
To "；Radix Angelicae Pubescentis, pungent scattered hardship is dry, and no matter newly tepor can lead to, function expelling wind and eliminating dampness, numbness relieving and pain relieving, all wind-cold-dampness arthralgias, arthralgia,
Long, can apply, be with diseases such as the numbness pain of lower part, soreness of waist and knee joint, two sufficient ruffian numbness, joint stuffiness especially it is suitable, be often equal with radix achyranthis bidentatae
With." wood grass, which converges, to be sayed ": " benefaction blood system, the medicine of the wet cold dispelling of wind-dispelling row.The card of all disease wind, if head term is unable to pitching, waist and knee cannot
It bends and stretches or numbness pain is difficult to walk, numbness does not have to, all wind and cold caused, heat and wet institute wound；Must be warm with the toil of Radix Angelicae Pubescentis, it is living
It takes offence blood, cold dispelling heresy of dispelling "." wood grass justice ": " smell hero is strong, and sweet perfumes are diffused all around, therefore can declare logical hundred arteries and veins, reconciliation channels and collaterals, logical muscles and bones and
Sharp organ, the numbness of all cold-dampness in muscle, in joint person, the strong taste of this non-used gas hero taste, cannot go directly in passages through which vital energy circulates joint it
Between, therefore the medicine essential for the soft all big cards of wandering arthritis ruffian；Pheretima, it is salty-cold, return liver, spleen, bladder meridian.Relieving convulsion and spasm, clearing and activating the channels and collaterals,
It dispels the stasis of bloods of channels and collaterals, is longer than to walk to alter and remove obstruction in channels to relieve pain, therefore for treating blood stagnancy due to deficiency of QI hemiplegia and bi Zheng podomere is unfavorable.It is equipped with chicken again
Blood rattan blood circulation promoting nourishes blood, activating muscle and blood can invigorate blood circulation and blood-nourishing, and have the function of relaxing tendons and activating collaterals, to extremity numbness, rheumatic arthralgia
Equal diseases, no matter the deficiency of blood, the stasis of blood is stagnant can apply；Safflower, promoting blood circulation, swelling and pain relieving." drugization justice ": " safflower is apt to promoting blood circulation,
For gas medicine in blood, it can rush down and can mend, respectively there is wonderful justice ".This product is kind can be promoting blood circulation, energy promoting blood circulation, swelling and pain relieving.It plays and dispels altogether
The all heresies of wind, cold, wet, heat, phlegm, the stasis of blood, the resistance of degrading the channel numbness, heresy remove Maitong, and it is altogether adjutant that all card natures, which are readily solved,.
Major function: invigorating kidney, promoting blood circulation, numbness relieving and pain relieving.For deficiency of kidney-essence, joint secret anguish or shouting pain caused by obstruction of collaterals by blood stasis,
Fixed pain, very, spinal column is powerless, joint joint stuffiness for hypnalgia.Osteoarthritis is shown in above-mentioned patient.
In conclusion the Chinese medicine composition prescription that numbness is led in kidney tonifying of the invention is delayed day more according to the Osteoarthritis course of disease
Long, and the state of an illness is touching refractory, the feature of asthenia in origin and asthenia in superficiality, using tonification and purgation in combination, residence passes through the big method of mending, and has eliminating evil without hurting just
Prescription feature.All medicines share, plays " kidney-replenishing blood-nourishing promoting blood circulation, the therapy of active numbness relieving and pain relieving " invigorating kidney, promoting blood circulation altogether, numbness relieving and pain relieving it
Function.
Through testing, traditional Chinese medicine composition for treating Osteoarthritis clinical efficacy of the invention is significant.
Specific embodiment
Embodiment below facilitates a better understanding of the present invention, but does not limit the present invention.Experiment in following embodiments
Method is unless otherwise specified conventional method.Test material as used in the following examples is unless otherwise specified city
It sells.
Embodiment 1
The Chinese medicine composition that numbness is led in kidney tonifying of the invention is made of following bulk pharmaceutical chemicals:
Rehmannia glutinosa 15g rhizome of davallia 15g Radix Astragali 30g Radix Angelicae Sinensis 15g
Radix achyranthis bidentatae 15g Cortex Eucommiae 15g Rhizoma Chuanxiong 12g radix saposhnikoviae 12g
Radix Angelicae Pubescentis 12g pheretima 9g Caulis Spatholobi 15g safflower 12g.
Kidney tonifying of the invention lead to the Chinese medicine composition of numbness the preparation method comprises the following steps:
Radix Astragali, Rhizoma Chuanxiong are ground into fine powder.10 taste such as remaining radix rehmanniae preparata, Cortex Eucommiae, pheretima, Caulis Spatholobi adds 10 times of weight waters to extract
2 times, first time 2h, second of 1h, collecting decoction, filtration, filtrate be condensed into relative density be 1.30 ~ 1.35(60 DEG C) it is thick
Cream mixes with above-mentioned fine medicinal material powder (1:1.5), 1000 balls is made, dry, polishing to get.
Discrimination method:
(1) this product 5g is taken, it is finely ground, add methanol 30ml, be heated to reflux 1 hour, let cool, filter, filtrate is evaporated, and residue adds first
Alcohol 1ml makes to dissolve, as test solution.Aurantiin reference substance separately is taken, adds methanol that solution of every 1ml containing 0.5mg is made, as
Reference substance solution.It is tested according to thin-layered chromatography (VI B of annex), draws each 4 μ l of above two solution, put respectively in same silica G
On lamellae, using toluene-ethyl acetate-formic acid-water (1: 12: 2.5: 3) upper solution as solvent, it is unfolded, takes out,
It dries, sprays with alchlor test solution, set and inspected under ultraviolet lamp (365nm).In sample chromatogram, corresponding to reference substance chromatography
Position on, show same color fluorescence spot.
(2) this product 6g is taken, it is finely ground, add methanol 30ml, be ultrasonically treated 40 minutes, filtration, filtrate, which is concentrated into, closely does, and residue adds
Water 10ml, low-grade fever make to dissolve, and the n-butanol shaking being saturated with water is extracted 2 times, each 20ml, merge n-butanol liquid；Use ammonia solution
Washing 2 times, each 20ml discards ammonia solution；It is washed with water and washs 2 times, each 20ml discards aqueous；N-butanol liquid is evaporated, residue
Add water 5ml, low-grade fever makes to dissolve, and by D101 type large pore resin absorption column (internal diameter 1.5cm, pillar height 12cm) after cooling, uses
Water 50ml elution discards aqueous, then is eluted with 40% ethyl alcohol 30ml, discards eluent, continues to be eluted with 70% ethyl alcohol 80ml, collect
Eluent is evaporated, and residue adds methanol 1ml to make to dissolve, as test solution.Radix Astragali control medicinal material 1g separately is taken, is made in the same way of pair
According to medicinal material solution.Astragaloside IV reference substance is taken again, adds methanol that solution of every 1ml containing 1mg is made, as reference substance solution.According to thin
Layer chromatography (one VI B of annex of " Chinese Pharmacopoeia " version in 2010) test, draws test solution and control medicinal material solution each 5
μ l, 2 μ l of reference substance solution are put respectively on same silica gel g thin-layer plate, with [n-butanol-ethyl acetate-water (4: 1: 5) upper layer
Solution]-methanol (10: 1) be solvent, be unfolded, take out, dry, spray with 10% ethanol solution of sulfuric acid, be heated to spot at 105 DEG C
Colour developing is clear.In sample chromatogram, on position corresponding with control medicinal material and reference substance chromatography, identical brown color spot is shown
Point.
(3) this product powder lg is taken, add diethyl ether 20ml, is heated to reflux l hours, filters, and filtrate volatilizes, and residue adds ethyl acetate
2ml makes to dissolve, as test solution.Rhizoma Chuanxiong control medicinal material lg separately is taken, is made in the same way of control medicinal material solution.It takes in lovage again
Ester A reference substance adds ethyl acetate that solution (set in brown measuring bottle) of every 1ml containing 0.1mg is made, as reference substance solution.According to thin
Layer chromatography (VI B of annex) test, draws above-mentioned each l0 μ l of three kinds of solution, is put respectively in same silica G F254On lamellae, with
N-hexane-ethyl acetate (3: 1) is solvent, is unfolded, and takes out, dries, set and inspect under ultraviolet lamp (254nm).Test sample color
In spectrum, on position corresponding with reference medicine chromatography and reference substance chromatography, the spot of same color is shown.
The pharmacodynamic test of the Chinese medicine composition of the invention of embodiment 2
One, clinical trial process
1. general information 70 patients of this group are all from January, 2013 in January, 2015 Xinjiang Uygur Autonomous Regions's Chinese medicine
Hospital orthopedics consulting patients in out-patient department is randomly divided into two groups.Treatment group 35, wherein male 16, female 19, average age 59 years old.
Control group 35, male 13, female 22, average age 60 years old.Two groups of cases meet diagnostic criteria.It is statistically analyzed, it is poor
Different no significant, is comparable (P > 0.05).
It is included in and exclusion criteria
(1) it is included in the knee osteoarthritis diagnosis mark that standard Western medicine diagnostic criteria is proposed referring to U.S.'s rheumatism association (ACR)
Clinical plus radiological examination two sets of standards in standard, i.e., must have a pain of the knee joint, and 1 in spur 2, and it is at least following
1 in 3: age>40 year old, morning stiffness<30min and bony crepitus, tenderness bone increases and joint is without apparent temperature.It is all to meet
Wherein 1 set of standard can be made a definite diagnosis.
TCM syndrome diagnostic criteria kidney deficiency blood stasis type: is closed referring to Standards for Diagnosis and Curative Effect of Chinese Medical Symptom, " Diagnostics of Chinese Medicine "
Secret anguish or shouting pain are saved, sore spot is fixed or joint deformity, and activity is unfavorable, dizzy with soreness and weakness of waist and knees, tinnitus, dim complexion, and tongue nature is light
The dark or stasis of blood is purple, and tongue fur is thin white, deep thready pulse.
(2) the exclusion criteria age was in 75 years old or more person；High blood pressure blood pressure is higher than 140/90mmHg person；Gestation or lactation
Phase women；Allergic constitution person.
Treatment method:
Treatment group: give the embodiment of the present invention 1 preparation kidney tonifying numbness lead to ball (recipe form Rehmannia glutinosa, the rhizome of davallia, Radix Astragali,
Radix Angelicae Sinensis, radix achyranthis bidentatae, Cortex Eucommiae, Rhizoma Chuanxiong, Radix Angelicae Pubescentis, radix saposhnikoviae, pheretima, Caulis Spatholobi, safflower.), by Hospital of TCM, Xinjiang Uygur Autonomous Region
Medicine Drug Manufacturing Room provide.Each 10g takes orally before meals 3 times a day.
Control group: took celecoxib capsule (pfizer inc's production, national drug standard J20030098), daily 1
Secondary, each 200mg, swelling and pain deactivate after mitigating；(Shanghai Pharmaceutical (Group) Co., Ltd. believes that friendship pharmacy head factory is raw to methotrexate
Produce, national drug standard H31020644) it is oral, 1 times a week, each 10mg.Two groups of courses for the treatment of are 3 months.
Observation index and method
(1) the more pretherapy and post-treatment arthralgia index of sings and symptoms, articular pain number (a), joint swelling index, pass
Section swelling number (a), function of joint classification, morning stiffness time (min), both hands are averaged grip (mmHg) and 15m walking time (s) etc.
Sings and symptoms.
(2) lab index measures erythrocyte sedimentation rate (ESR), RF and c reactive protein (CRF) etc. before and after treatment.
Efficacy assessment standard: it is formulated referring to " new Chinese medicine guideline of clinical investigations ".Effective: cardinal symptom, sign are whole
Body improvement rate >=75%；ESR and CRP is normal or is obviously improved or approaches and is normal.Progress: cardinal symptom, sign entirety improvement rate >=
50%；ESR and CRP have improvement.It is effective: cardinal symptom, sign entirety improvement rate >=30%；ESR and CRP has improvement or without improvement.
It is invalid: cardinal symptom, sign entirety improvement rate < 30%；ESR and CRP are without improvement.
Statistical method
For statistical analysis using 16.0 statistical software of SPSS, continuous data is indicated with mean ± standard deviation (x ± s), group
Between compare and examined using t, remaining detection uses one-way analysis of variance, and P < 0.05 is that difference is statistically significant.
Two, interpretation of result
1. two groups of patient clinical curative effects compare
Control group (P < 0.05) is apparently higher than by comparing discovery treatment group's total effective rate.
1 two groups of patient clinical curative effects of table compare (example/%)
Note: compared with the control group, P < 0.05 *.
2. the pretherapy and post-treatment major laboratories index variation of two groups of patients is compared
As shown in table 2, ESR, CRP, RF have clear improvement (P < 0.05) after two groups of treatments, and treatment group and control group are treated
After compare, ESR difference is statistically significant (P < 0.05).
Table 2 two groups of patients pretherapy and post-treatment ESR, RF and CRP compare ()
Note: with this group before treatment, P < 0.05 *；Compared with after control group treatment, P < 0.05 △.
Compared with 3. two groups of patient's cardinal symptoms change with sign: two groups of pretherapy and post-treatment articular pain numbers, swelling numbers, arthritis
Bitterly, tenderness, swelling index, function of joint grade, morning stiffness time, two hands are averaged grip, 15m walking time, and difference has statistics
Meaning (P < 0.05), compared with the control group, above-mentioned each indicator difference is also statistically significant (P < 0.05) for treatment group after treatment.
4. two groups of patient safeties compare: there are 2 generation adverse reactions, incidence 4% in treatment group；Control group has 3 hairs
Raw adverse reaction, incidence 6%, two groups are compared no difference of science of statistics (P > 0.05).Treatment group's adverse reaction show as fash or
Digestive discomfort, degree are slight；Control group adverse reaction is mainly shown as that leucocyte decline, alanine aminotransferase increase
Deng degree is slight.Two groups of adverse reactions disappear after symptomatic treatment.
Research conclusion: treatment group's total effective rate is apparently higher than control group (P < 0.05), and two groups of pretherapy and post-treatment arthralgias swell
Be averaged grip, 15m walking time difference of swollen, function of joint grade, morning stiffness time, two hands is statistically significant (P < 0.05), controls
Compared with the control group, difference is statistically significant (P < 0.05) for These parameters after the treatment for the treatment of group.ESR, CRP, RF after two groups of treatments
Improve (P < 0.05) before relatively treating, wherein ESR improves treatment group and is better than control group (P < 0.05)；Treatment group and control group are bad
Reacting incidence is respectively 4%, 6%, and two groups of comparing differences are not statistically significant (P > 0.05).
To sum up, it is significant to lead to ball treatment Osteoarthritis clinical efficacy to kidney tonifying numbness of the invention.
Finally, it should be noted that the foregoing is only a preferred embodiment of the present invention, it is not intended to restrict the invention,
Although the present invention is described in detail referring to the foregoing embodiments, for those skilled in the art, still may be used
To modify the technical solutions described in the foregoing embodiments or equivalent replacement of some of the technical features.
All within the spirits and principles of the present invention, any modification, equivalent replacement, improvement and so on should be included in of the invention
Within protection scope.
Claims (10)
1. a kind of kidney tonifying lead to numbness Chinese medicine composition, it is characterised in that: the Chinese medicine composition by following mass fraction each original
Expect that medicine forms: 15 parts of Rehmannia glutinosa, 15 parts of the rhizome of davallia, 30 parts of Radix Astragali, 15 parts of Radix Angelicae Sinensis, 15 parts of radix achyranthis bidentatae, 15 parts of Cortex Eucommiae, 12 parts of Rhizoma Chuanxiong,
12 parts, 12 parts of Radix Angelicae Pubescentis, 9 parts of pheretima, 15 parts of Caulis Spatholobi, 12 parts of safflower of radix saposhnikoviae.
2. the preparation method of Chinese medicine composition described in claim 1, it is characterised in that: steps are as follows:
(1) Radix Astragali of formula ratio, rhizome of chuanxiong are ground into fine powder；
(2) remaining 10 taste is extracted with water 2 times, collecting decoction, after filtering, filtrate is condensed into thick paste;
(3) fine powder being added in step (1) mixes, and pill is made.
3. according to the method described in claim 2, it is characterized by: it is in bulk pharmaceutical chemicals mixture that water described in step (2), which mentions,
10 times of water is added to extract.
4. according to the method described in claim 2, it is characterized by: extracting described in step (2) is for 2 times to extract 2h for the first time,
Second of extraction 1h.
5. according to the method described in claim 2, it is characterized by: in step (2) by filtrate be condensed into relative density be 1.30 ~
1.35(60 DEG C) thick paste.
6. application of the Chinese medicine composition described in claim 1 in the drug that rheumatism is led in preparation treatment kidney tonifying.
7. application of the Chinese medicine composition described in claim 1 in the drug of preparation treatment Osteoarthritis.
8. a kind of drug, effective component is Chinese medicine composition described in claim 1.
9. a kind of drug according to claim 8, it is characterised in that: the dosage form of the drug is pill.
10. a kind of drug according to claim 8, it is characterised in that: further include medically acceptable in the drug
Auxiliary material.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610432607.6A CN105943700B (en) | 2016-06-17 | 2016-06-17 | The Chinese medicine composition and its preparation method and application of numbness is led in a kind of kidney tonifying |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610432607.6A CN105943700B (en) | 2016-06-17 | 2016-06-17 | The Chinese medicine composition and its preparation method and application of numbness is led in a kind of kidney tonifying |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105943700A CN105943700A (en) | 2016-09-21 |
| CN105943700B true CN105943700B (en) | 2019-11-01 |
Family
ID=56907129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610432607.6A Active CN105943700B (en) | 2016-06-17 | 2016-06-17 | The Chinese medicine composition and its preparation method and application of numbness is led in a kind of kidney tonifying |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105943700B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109172751B (en) * | 2018-11-14 | 2021-07-16 | 山东中医药大学 | Traditional Chinese medicine rehabilitation and repair medicinal liquor for knee osteoarthritis and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101773561A (en) * | 2009-01-13 | 2010-07-14 | 北京亚东生物制药有限公司 | Chinese medicine composition with functions of tonifying kidney, invigorating blood circulation and relieving pain and preparation method thereof |
| CN102579616A (en) * | 2012-03-15 | 2012-07-18 | 李小波 | Chinese medicine capsulate for treating osteoarthritis for elderly people |
| CN103263560A (en) * | 2013-04-26 | 2013-08-28 | 北京中医药大学东方医院 | Traditional Chinese medicine composition having effects of tonifying kidney and dredging collaterals and preparation method thereof |
-
2016
- 2016-06-17 CN CN201610432607.6A patent/CN105943700B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101773561A (en) * | 2009-01-13 | 2010-07-14 | 北京亚东生物制药有限公司 | Chinese medicine composition with functions of tonifying kidney, invigorating blood circulation and relieving pain and preparation method thereof |
| CN102579616A (en) * | 2012-03-15 | 2012-07-18 | 李小波 | Chinese medicine capsulate for treating osteoarthritis for elderly people |
| CN103263560A (en) * | 2013-04-26 | 2013-08-28 | 北京中医药大学东方医院 | Traditional Chinese medicine composition having effects of tonifying kidney and dredging collaterals and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| "辨证施治膝骨性关节炎81例";叶芳等;《陕西中医》;20051225;第26卷(第12期);第1303页左栏倒数5行、右栏倒数13行 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105943700A (en) | 2016-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101066303A (en) | Medicine for treating cerebral thrombus, cerebral angiosclerosis, apoplexy and hemiplegia and its prepn | |
| CN102205026A (en) | Chinese medicinal composition for treating children chronic sinusitis and preparation method thereof | |
| CN104666579A (en) | Traditional Chinese medicine composition for treating gonarthromeningitis and preparation method of traditional Chinese medicine composition | |
| CN102772712B (en) | Traditional Chinese medicine composition for treating heat-toxicity, flourishing and blood stasis type diabetic foot | |
| CN104815318A (en) | Traditional Chinese medicine preparation for treating gout | |
| CN103071134B (en) | External preparation for treating rheumatic arthrodynia and traumatic pain and swelling and preparation method thereof | |
| CN103083592B (en) | Traditional Chinese medicine for treating gouty arthritis | |
| CN104623376B (en) | Be used for the treatment of prosopalgic medicine | |
| CN105943700B (en) | The Chinese medicine composition and its preparation method and application of numbness is led in a kind of kidney tonifying | |
| CN105943705A (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis and preparation method thereof | |
| CN104524174A (en) | Traditional Chinese medicine composition for treating rheumatic arthralgia and preparation method thereof | |
| CN108465059A (en) | Treat the Chinese medicine composition of wind chill blockage and qi stagnation and blood stasis type cervical spondylosis, the preparation method of Chinese medicine preparation and pill | |
| CN103735647A (en) | Medicated wine for treating chronic infectious arthritis | |
| CN104474114A (en) | Traditional Chinese medicine composition for treating kidney-yang deficiency type lumbar muscle strain and preparation method of traditional Chinese medicine composition | |
| CN108186749A (en) | Treat Chinese medicine composition of cervical spondylosis and preparation method thereof | |
| CN103520427B (en) | Traditional Chinese medicine for treating body-resistance-weak and pathogen-strong type chronic osteomyelitis and preparation method thereof | |
| CN103599379B (en) | Traditional Chinese medicine for treatment of liver and kidney deficient type chronic osteomyelitis and its preparation method | |
| CN105688059A (en) | Traditional Chinese medicine preparation with folium artemisiae argyi for treating osteoproliferation through external application | |
| CN104840865A (en) | Traditional Chinese medicine preparation for treating gouty arthritis | |
| CN110141622A (en) | A kind of Chinese medicine composition and its preparation method and application for treating pain | |
| CN104274540B (en) | Chinese medicine composition, preparation method and use containing tripterygium wilfordii | |
| CN103272129B (en) | Traditional Chinese medicine composition for treating neurodermatitis | |
| CN118453799A (en) | Traditional Chinese medicine composition for treating gonarthromeningitis and preparation method thereof | |
| Chen | Herbology in Three Traditional Medicines for Acne | |
| CN105560427A (en) | Transdermal gate-freeing powder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |